CorMedix Inc.

CRMD

CorMedix Inc.

CRMD

Insider Sentiment (TTM):

Last Purchase:2025-10-23Last Sale:2026-01-21Shares Purchased (TTM):25,000Shares Sold (TTM):388,121

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:39,985,226Shares Outstanding:79,509,000Institutional Ownership Pct.:50.29%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	257	178	145	48	159	66	41	35	29	35	44	53
Restricted Cash Current	-	-	0	-	-	-	0	-	-	0	0	0
Short Term Investments	0	0	4	7	31	11	11	11	17	23	32	33
Accounts Receivable Net Current	161	155	171	159	43	55	52	17	0	-	-	-
Inventory Net	39	31	30	29	10	7	8	7	4	2	2	-
Prepaid Expense Current	-	-	-	-	0	0	0	0	0	0	0	1
Prepaid Expense And Other Assets Current	24	19	18	16	5	5	4	3	3	2	1	1
Assets Current	481	383	367	260	248	145	115	73	53	63	79	89
Property Plant And Equipment Net	8	6	6	4	2	2	2	2	2	2	2	2
Other Assets	-	-	-	-	1	1	-	-	-	-	-	-
Other Long Term Investments	27	24	24	23	-	-	0	-	-	-	-	-
Goodwill	30	30	30	18	-	-	-	-	-	-	-	-
Intangible Assets Net Excluding Goodwill	358	369	379	390	2	2	2	2	-	-	-	-
Restricted Cash Noncurrent	-	-	-	-	0	0	0	0	0	0	0	0
Deferred Income Tax Assets Net	0	3	16	53	-	-	-	-	-	-	-	-
Operating Lease Right Of Use Asset	-	-	3	3	0	0	0	1	1	1	1	1
Finance Lease Right Of Use Asset	-	-	1	1	-	-	-	-	-	-	-	-
Assets	904	816	826	751	253	150	119	78	58	68	82	91
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	10	13	8	20	6	2	2	1	3	3	4	2
Accrued Liabilities Current	173	113	162	109	26	32	32	17	8	7	7	5
Operating Lease Liability Current	-	-	1	1	0	0	0	0	0	0	0	0
Finance Lease Liability Current	-	-	1	1	-	-	-	-	-	-	-	-
Liabilities Current	187	129	174	134	32	34	34	18	11	10	11	8
Deferred Tax Liabilities Other	145	145	145	145	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	-	-	2	2	0	0	0	0	0	0	1	1
Finance Lease Liability Noncurrent	-	-	1	1	-	-	-	-	-	-	-	-
Other Liabilities Noncurrent	2	3	-	-	-	-	-	-	-	-	-	-
Liabilities	443	379	421	377	32	35	34	19	12	10	12	8
Stockholders Equity
Preferred Stock Value	0	0	-	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	573	575	582	565	520	434	424	412	396	394	392	390
Retained Earnings Accumulated Deficit	-112	-138	-177	-191	-299	-319	-340	-353	-350	-336	-322	-307
Stockholders Equity	461	437	405	374	221	115	85	59	46	58	70	83
Liabilities And Stockholders Equity	904	816	826	751	253	150	119	78	58	68	82	91
Restricted Cash	-	-	-	1	-	-	-	-	-	-	-	-
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	2	2	2	2	2	2	2	2	2	2	2	2
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	160	160	160	160	160	160	160	160	160	160	160	160
Common Stock Shares Issued	78	78	79	78	75	68	64	58	55	55	55	55
Shares Outstanding	78	78	79	78	75	68	64	58	55	55	55	55

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	5.42%	10.34%	-5.55%	-	-	-	-	-	-	-	-	-
2025	8.78%	12.01%	2.96%	37.19%	4.53%	3.33%	-7.53%	6.48%	-32.05%	6.51%	17.78%	26.67%
2024	-2.59%	-19.96%	-16.08%	17.07%	80.89%	103.05%	-0.90%	-14.73%	21.09%	4.50%	67.30%	98.37%
2023	-	-	-	-	-	-	13.74%	8.31%	-0.96%	37.72%	70.76%	54.09%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.56	2.98	2.11	1.94	7.82	4.21	3.39	3.96	4.79	6.65	6.97	11.61
Quick Ratio	2.23	2.59	1.83	1.60	7.51	3.99	3.16	3.59	4.41	6.38	6.75	11.45
Working Capital	293.16M	254.34M	192.78M	125.89M	216.35M	110.47M	80.74M	54.67M	42.08M	53.88M	68.05M	81.39M
Leverage & Debt
Debt to Equity	0.96	0.87	1.04	1.01	0.14	0.30	0.40	0.32	0.25	0.17	0.17	0.10
Interest Coverage TTM	78.49	69.87	53.97	106.67	1,359.11	439.98	-683.19	-1,150.26	-1,399.00	-1,326.17	-1,219.49	-1,135.59
Debt Ratio	0.49	0.46	0.51	0.50	0.13	0.23	0.29	0.24	0.20	0.15	0.15	0.09
Efficiency & Turnover
Asset Turnover TTM	0.80	0.83	0.66	0.52	0.78	0.76	0.43	0.15	0.01	0.00	0.00	0.00
Days Sales Outstanding TTM	80.63	95.53	130.50	149.85	64.77	241.46	433.70	517.56	93.43	-	-	-
Receivables Turnover TTM	4.53	3.82	2.80	2.44	5.63	1.51	0.84	0.71	3.91	-	-	-
Per Share Metrics
Diluted EPS TTM	2.02	1.95	2.03	1.88	0.71	0.25	-0.30	-0.78	-0.92	-0.87	-0.91	-0.70
Free Cash Flow Per Share TTM	3.19	2.45	2.40	0.98	0.45	-0.21	-0.86	-0.95	-0.89	-0.79	-0.76	-0.60
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	82.78%	85.83%	88.46%	92.61%	95.62%	95.19%	92.66%	-	-	-	-	-
Operating Profit Margin TTM	46.95%	48.41%	48.17%	48.51%	40.60%	17.53%	-51.43%	-415.59%	-7,212.47%	-	-	-140,321.43%
Net Profit Margin TTM	40.49%	45.25%	52.31%	75.83%	42.11%	20.81%	-41.24%	-376.35%	-6,589.10%	-	-	-133,978.01%
Growth Metrics
Net Revenue Growth (1Y)	280.50%	384.60%	617.03%	1,647.67%	14,970.27%	-	-	41,184.20%	2,107.40%	-100.00%	-100.00%	-67.75%
Net Income Growth (1Y)	265.86%	953.61%	-1,009.40%	-452.12%	-196.32%	-134.20%	-61.31%	15.97%	43.93%	51.16%	56.02%	35.89%
EPS Growth (1Y)	216.81%	764.58%	-843.23%	-372.80%	-181.70%	-130.14%	-66.54%	11.49%	13.32%	15.90%	23.44%	-1.04%
Valuation Metrics
P/E TTM	3.29	2.98	5.14	5.43	16.36	23.39	-26.60	-10.30	-4.70	-4.85	-4.13	-5.26
P/B TTM	1.34	1.24	2.07	2.36	3.79	3.50	5.63	8.10	5.40	4.20	2.73	2.51
P/S TTM	1.33	1.35	2.69	4.12	6.89	4.87	10.97	38.76	309.51	-	-	7,044.87
Market Cap	615.79M	539.87M	837.76M	883.07M	836.87M	401.90M	476.86M	475.31M	249.50M	243.81M	191.40M	209.25M
Enterprise Value	358.11M	360.79M	693.11M	834.72M	677.46M	335.51M	436.11M	439.92M	220.85M	208.45M	147.57M	155.75M
Calculated Values
Free Cash Flow TTM	250.42M	194.71M	172.79M	74.42M	30.41M	-13.63M	-50.73M	-56.15M	-51.20M	-45.70M	-38.74M	-33.98M
Net Debt	-257.68M	-179.08M	-144.64M	-48.34M	-159.41M	-66.39M	-40.76M	-35.39M	-28.65M	-35.36M	-43.82M	-53.50M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-21Sale

Owner: Dillione, Janet

Title: -

Shares: 10,000

Price/Share: $6.88

Value: $68,800.00

Shares Owned: 38,473

Relationship: Director

Ownership: Direct

2025-12-30Sale

Owner: Dunton, Alan W

Title: -

Shares: 20,000

Price/Share: $13.00

Value: $260,000.00

Shares Owned: 40,250

Relationship: Director

Ownership: Direct

2025-12-18Sale

Owner: Todisco, Joseph

Title: Chief Executive Officer

Shares: 30,000

Price/Share: $12.00

Value: $360,000.00

Shares Owned: 509,496

Relationship: Director,Officer

Ownership: Direct

2025-12-09Sale

Owner: Lefkowitz, Steven W

Title: -

Shares: 40,000

Price/Share: $11.88

Value: $475,200.00

Shares Owned: 80,498

Relationship: Director

Ownership: Direct

2025-12-09Sale

Owner: Dillione, Janet

Title: -

Shares: 34,000

Price/Share: $12.00

Value: $408,000.00

Shares Owned: 48,473

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-21	Dillione, Janet	Director	-	Direct	Sale	10,000	6.88	$68,800.00	38,473	4
2025-12-30	Dunton, Alan W	Director	-	Direct	Sale	20,000	13.00	$260,000.00	40,250	4
2025-12-18	Todisco, Joseph	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	12.00	$360,000.00	509,496	4
2025-12-09	Lefkowitz, Steven W	Director	-	Direct	Sale	40,000	11.88	$475,200.00	80,498	4
2025-12-09	Dillione, Janet	Director	-	Direct	Sale	34,000	12.00	$408,000.00	48,473	4
2025-12-02	Dillione, Janet	Director	-	Direct	Sale	46,657	10.00	$466,570.00	48,473	4
2025-11-24	Dillione, Janet	Director	-	Direct	Sale	26,343	9.93	$261,585.99	48,473	4
2025-11-14	Dillione, Janet	Director	-	Direct	Sale	30,000	11.42	$342,600.00	48,473	4
2025-10-23	Kaplan, Myron	Director	-	Direct	Purchase	25,000	11.02	$275,500.00	201,034	4
2025-09-12	Todisco, Joseph	Officer	Chief Executive Officer	Direct	Sale	50,000	13.00	$650,000.00	509,496	4
2025-09-12	Dunton, Alan W	Director	-	Direct	Sale	10,000	13.13	$131,300.00	40,250	4
2025-09-11	Hurlburt, Elizabeth	Officer	Chief Operating Officer	Direct	Sale	41,121	13.08	$537,862.68	176,990	4
2025-09-09	Zelnick, Kaufman Beth	Officer	Chief Legal Officer	Direct	Sale	50,000	13.12	$656,000.00	180,418	4
2024-11-14	Hurlburt, Elizabeth	Officer	EVP	Direct	Sale	140,027	11.18	$1,565,501.86	45,397	4
2024-10-31	Mistry, Erin	Officer	EVP, Chief Commercial Officer	Direct	Purchase	1,500	9.99	$14,985.00	52,011	4
2024-03-13	Todisco, Joseph	Director,Officer	Chief Executive Officer	Direct	Purchase	13,561	3.74	$50,718.14	352,839	4
2023-12-15	Dunton, Alan W	Director	-	Direct	Purchase	3,000	3.30	$9,900.00	15,250	4
2023-11-17	Mistry, Erin	Officer	Chief Commercial Officer	Direct	Purchase	1,000	4.00	$4,000.00	4,900	4
2023-09-08	Todisco, Joseph	Director,Officer	Chief Executive Officer	Direct	Purchase	10,000	3.71	$37,100.00	219,726	4
2023-05-18	Kaplan, Myron	Director	-	Direct	Purchase	6,000	4.54	$27,240.00	166,034	4
2023-05-17	Costa, Paulo F	Director	-	Direct	Purchase	10,000	4.65	$46,500.00	10,000	4/A
2023-05-17	Dunton, Alan W	Director	-	Direct	Purchase	3,000	4.33	$12,990.00	9,250	4/A
2023-05-17	Todisco, Joseph	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	4.58	$22,900.00	209,726	4/A
2023-05-17	Stewart, Robert A	Director	-	Direct	Purchase	10,000	4.37	$43,700.00	11,000	4/A
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

50.29%

Inst. Shares: 39,985,226

Shares Outstanding: 79,509,000

2025-12-31

57.50%

Inst. Shares: 41,421,410

Shares Outstanding: 72,034,000

2025-09-30

56.20%

Inst. Shares: 42,670,756

Shares Outstanding: 75,930,243

2025-06-30

49.17%

Inst. Shares: 33,398,718

Shares Outstanding: 67,927,710

2025-03-31

34.71%

Inst. Shares: 22,643,879

Shares Outstanding: 65,244,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	39,985,226	79,509,000	50.29%
2025-12-31	41,421,410	72,034,000	57.50%
2025-09-30	42,670,756	75,930,243	56.20%
2025-06-30	33,398,718	67,927,710	49.17%
2025-03-31	22,643,879	65,244,000	34.71%
2024-12-31	22,031,298	58,872,000	37.42%
2024-09-30	18,428,778	58,825,221	31.33%
2024-06-30	16,521,759	57,620,974	28.67%
2024-03-31	16,482,623	57,503,154	28.66%
2023-12-31	17,899,915	50,902,931	35.16%
2023-09-30	17,254,862	56,553,174	30.51%
2023-06-30	18,632,494	45,365,635	41.07%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

CorMedix Inc. (CRMD) — SEC Financial Statements & Analysis

CorMedix Inc. (CRMD) is a pharmaceutical preparations company, incorporated in DE. CorMedix Inc. trades on Nasdaq as: CRMD. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), CorMedix Inc. reported a 280.50% year-over-year revenue growth, a Gross Profit Margin of 82.78% (TTM), a Debt-to-Equity ratio of 0.96x, a Price-to-Sales (P/S) ratio of 1.33x (TTM), a Price-to-Book (P/B) ratio of 1.34x (TTM), at a market cap of $615.79M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 280.50%
Gross Profit Margin TTM: 82.78%
Debt To Equity: 0.96x
P/S TTM: 1.33x
P/B TTM: 1.34x
Market Cap: $615.79M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CorMedix Inc. in?

CorMedix Inc. (CRMD) operates in the Pharmaceutical Preparations industry.

What is CRMD's market cap?

CorMedix Inc. (CRMD) has a market capitalization of $615.79M as of 2026-06-30.

What is CRMD's P/E ratio?

CorMedix Inc. (CRMD)'s trailing twelve month P/E ratio is 3.29x as of 2026-06-30.

What exchange does CRMD trade on?

CorMedix Inc. (CRMD) trades on the Nasdaq.

Where is CorMedix Inc. incorporated?

CorMedix Inc. is incorporated in DE.

CorMedix Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

CorMedix Inc. (CRMD) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

CorMedix Inc. (CRMD) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.